LivaNova (Nasdaq: LIVN) shares ticked up before hours today on third-quarter results that beat the consensus forecast.
Shares of LIVN rose 1.7% to $54.83 apiece in pre-market trading today.
The London-based medtech company reported profits of $26.8 million. That equals 49¢ per share on sales of $357.8 million for the three months ended Sept. 30, 2025.
LivaNova recorded an 18.8% bottom-line slide on a sales increase of 12.5%.
Adjusted to exclude one-time items, earnings per share came in at $1.11. That landed 19¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $342.7 million in revenue.
Cardiopulmonary sales grew 18% to $203.2 million. LivaNova attributed this growth to its Essenz Perfusion System sales and strong consumables demand. Additionally, the company’s Neuromodulation sales increased 6.9% to $149.5 million.
Following the strong quarter, LivaNova raised its full-year revenue guidance for between 8.5% and 9.5% on a constant currency basis. It also increased its adjusted EPS guidance by 10¢ at the midpoint, now expecting between $3.80 and $3.90. This marks the second consecutive quarter the company has increased its guidance.
Raised full-year 2025 revenue growth range 50 basis points to 8.5% to 9.5% on a constant-currency basis and 9.5% to 10.5% on an organic basis. Raised full-year 2025 adjusted diluted earnings per share range by $0.10 at midpoint to $3.80 to $3.90.
“LivaNova delivered another quarter of double-digit revenue growth, underscoring the durability of our Cardiopulmonary and Epilepsy businesses as a strong foundation for the company,” said Vladimir Makatsaria, CEO of LivaNova. “Disciplined execution, enhanced productivity, and operational excellence are driving operating margin expansion and cash generation, as we continue to reinvest in the core to sustain market leadership and advance innovation. At the same time, we are leveraging our Neuromodulation expertise to advance the obstructive sleep apnea and difficult-to-treat depression programs. We believe these efforts will position the company for long-term growth and expansion into attractive markets with large patient populations and significant unmet needs. We look forward to updating investors on our strategic priorities for each of these businesses at our upcoming Investor Day on November 12.”
